Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib plus fulvestrant: Results from MONALEESA-3

Fasching P, Esteva FJ, Pivot X, Nusch A, Beck JT, Chan A, Pieris-Gunatilaka A, Wang Y, Lanoue B, Chandiwana D, Neven P (2018)

Publication Type: Conference contribution

Publication year: 2018

Journal

Annals of Oncology Elsevier

Publisher: OXFORD UNIV PRESS

City/Town: OXFORD

Conference Proceedings Title: ANNALS OF ONCOLOGY

Event location: Munich DE

DOI: 10.1093/annonc/mdy272.282

Authors with CRIS profile

Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe

Involved external institutions

Highlands Oncology Group US United States (USA) (US) Novartis AG CH Switzerland (CH) NYU Langone Medical Center US United States (USA) (US) Breast Cancer Research Centre-Western Australia AU Australia (AU) University Hospital Leuven (UZ) / Universitaire ziekenhuizen Leuven BE Belgium (BE) Institut régional du Cancer de Montpellier (ICM) FR France (FR)

How to cite

APA:

Fasching, P., Esteva, F.J., Pivot, X., Nusch, A., Beck, J.T., Chan, A.,... Neven, P. (2018). Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib plus fulvestrant: Results from MONALEESA-3. In ANNALS OF ONCOLOGY. Munich, DE: OXFORD: OXFORD UNIV PRESS.

MLA:

Fasching, Peter, et al. "Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib plus fulvestrant: Results from MONALEESA-3." Proceedings of the 43rd ESMO Congress (ESMO), Munich OXFORD: OXFORD UNIV PRESS, 2018.

BibTeX: Download